BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31930541)

  • 1. Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
    Lu T; Wei D; Yu K; Ma D; Xiong J; Fang Q; Wang J
    Ann N Y Acad Sci; 2020 May; 1467(1):77-93. PubMed ID: 31930541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
    J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
    Wei D; Lu T; Ma D; Yu K; Li X; Chen B; Xiong J; Zhang T; Wang J
    J Cell Physiol; 2019 Apr; 234(4):5252-5263. PubMed ID: 30256411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
    Zhang J; Zhang M; Liang Y; Liu M; Huang Z
    Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
    [No Abstract]   [Full Text] [Related]  

  • 13. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
    Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
    Salas A; Ponnusamy S; Senkal CE; Meyers-Needham M; Selvam SP; Saddoughi SA; Apohan E; Sentelle RD; Smith C; Gault CR; Obeid LM; El-Shewy HM; Oaks J; Santhanam R; Marcucci G; Baran Y; Mahajan S; Fernandes D; Stuart R; Perrotti D; Ogretmen B
    Blood; 2011 Jun; 117(22):5941-52. PubMed ID: 21527515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
    Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
    Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.